MedTrace Logo

A Study of Guselkumab in Participants With Systemic Sclerosis

NCT04683029 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-07-23

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).

Conditions

  • Scleroderma, Systemic

Interventions

DRUG

Guselkumab Dose 1

Guselkumab Dose 1 will be administered intravenously.

DRUG

Guselkumab Dose 2

Guselkumab Dose 2 will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered intravenously or subcutaneously.

Sponsors & Collaborators

  • Janssen Pharmaceutical K.K.

    lead INDUSTRY

Principal Investigators

  • Janssen Pharmaceutical K.K., Japan Clinical Trial · Janssen Pharmaceutical K.K.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-24
Primary Completion
2023-05-17
Completion
2024-07-09

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04683029 on ClinicalTrials.gov